Jeder onkologisch tätige Arzt versucht, seine Patienten so effektiv wie möglich, aber mit nur so vielen Nebenwirkungen wie nötig zu behandeln. Zielgerichtete Therapien könnten diesen Traum durch die Definition bestimmter Subgruppen verwirklichen, indem bestimmte Tumorcharakteristika als prädiktive Faktoren für diese Therapien dienen. Seit einigen Jahren spielen solche Therapien eine wichtige Rolle bei der Behandlung des primären und metastasierten Brustkrebses. In diesem Artikel beschreiben wir einerseits die zielgerichteten Therapien, die bereits Einzug in den klinischen Alltag gefunden haben: so zum Beispiel der Antikörper Trastuzumab, der gegen HER2/neu gerichtet ist und sowohl beim primären als auch beim metastasierten Brustkrebs hervorragende Erfolge erzielt hat, oder der Antikörper Bevacizumab, der gegen den Liganden A des vaskulären epithelialen Wachstumsfaktors gerichtet ist. Andererseits möchten wir einen Ausblick geben auf die Substanzen und Therapiestrategien, die momentan unter klinischer Erprobung stehen.
Introduction
Every oncologist has a dream -doing more with less toxicity. Although we have achieved many improvements in treating cancer diseases by classical strategies, e.g. surgery, radiation and cytotoxic chemotherapy, we have also reached a limit with regard to the efficacy of drugs and schedules and the tolerability of side effects. Targeted therapies seem to be the key for an oncologist's dreams by defining subgroups of those patients who benefit Targeted Therapy: Can It Substitute for Chemotherapy?
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Universitätsfrauenklinik Heidelberg, Germany more from a specific treatment and those who do not. Most important in this process is the detection of special markers in tumour metabolism or tumour genetics that can predict the effect of a special drug. As a result of decades of research, new therapies are now becoming available in many cancer diseases. However, meanwhile we do realise step by step that, even as targeted as these therapies seem to be, they do have side effects that are sometimes very uncommon for oncologists, like hypertension, skin changes, and proteinuria. Interestingly, side effects are a mirror of their effects against specific pathways, regardless of whether they are physiological or cancer specific. Learning more about tumour biology and pathways will bring us closer to our dream of 'more with less'. For a few years now, targeted therapies have played a major role in the treatment of primary as well as metastatic breast cancer. Many clinicians are of the opinion that the invention of endocrine therapies, namely tamoxifen, has been the first step to a 'targeted' way to attack an oestrogen receptor-positive cancer disease. In fact, the discovery and the definition of the family of epidermal growth factor receptors (EGFRs) has been the real first approach to a targeted therapy in the new understanding.
EGFR Family
Many receptors exist to control cell behaviour. In cancer cells, the expression or activity of these receptors is deranged and often overactive. The EGFR family represents a group of transmembrane receptors with an extracellular part on the tumour cell's surface and an intracellular part. Up to now there are four different receptors described: EGFR, human epidermal receptor (HER)2/neu, HER3, and HER4. As far as we know, in breast cancer EGFR and HER2/neu are relevant. 20-25% of all primary breast cancer tumours are HER2/neu overexpressing and do have -without treatmenta worse prognosis than HER2/neu-negative tumours. Although researchers have not been able to identify any activator of HER2/neu, the receptor seems to play a central role in the biology of breast cancer cells. Receptors can be activated by special ligands, but they can also interact with other cell surface-based receptors. Both kinds of interaction lead to the activation of pathways inside the tumour cell that may lead to the expression of tumour cell characteristics like proliferation, migration, and invasion. There are two main ways to interfere with overactive receptors: antibodies to block a receptor's ligand or the receptor itself (so called 'mabs') and small molecules to block the intracellular activation of the receptor (so called 'nibs'). After years of preclinical as well as clinical studies, we know that the EGFR and HER2 pathway inside tumour cells can also be in- Schütz the outside to the inside of the cell. TKs can be inhibited by small molecules that are able to penetrate the cell membrane and block their enzymatic activity. In anti-HER2 therapy, all trials do have a clear message: Only treat patients with HER2 overexpression measured by immunohistochemistry or by fluorescent in situ hybridisation (FISH). Therefore, it is most important to carefully assess the HER2 status of every breast cancer patient.
Trastuzumab (Herceptin)
Trastuzumab has been described by Slamon and colleagues in the beginning of the 1990s as a humanised monoclonal antibody against EGFR-2 (HER2/neu) which is expressed on the surface of many primary as well as metastatic breast cancer tumour cells [1] . First clinical studies in metastatic breast cancer were disappointing due to the lack of patient group selection. However, researchers found out that patients having tumours with an overexpression of HER2 seemed to benefit more from the treatment than patients with tumours with lower or without any expression. Trastuzumab is the only medical treatment that has revealed to prolong life in metastatic breast cancer patients with HER2 overexpression in combination with chemotherapy [2, 3] . In primary breast cancer patients, trastuzumab is one of the most effective drugs for HER2-overexpressing tumours. In combination with [4] or given sequential to chemotherapy [5] , it nearly halves the number of recurrences (39-52%) and significantly prolongs overall survival at follow-up ranging between 1 and 3 years. Trastuzumab is well tolerated. The main toxicities consist in a reduction of the left ventricular ejection fraction with subsequent congestive cardiac failure (CCF) in 0.3-3.4% of all treated patients and anaphylactic reactions. Since CCF is a severe side effect especially in combination with anthracyclines, clinical trials of a combination therapy with trastuzumab without anthracyclines were developed. In a recently published trial with carboplatin and docetaxel, nearly no CCF was observed at all. The effectiveness of carboplatin and docetaxel in combination with trastuzumab was equivalent to the combination of anthracycline-containing chemotherapy with trastuzumab [6] . However, the most important lesson we have learned from all clinical HER2-positive trials is that only a single subgroup of patients benefits from this targeted therapy: those whose tumours overexpress HER2/neu. The others only seem to suffer from the side effects without improvement of their prognosis.
Lapatinib
The TK inhibitor (TKI) lapatinib inhibits both EGFR and HER2. Clinical trials have shown that in trastuzumab-pretreated metastatic breast cancer patients with HER2-overexpressing tumours a combination of capecitabine and lapatinib led to a better progression-free but not overall survival in comparison to capecitabine alone [7] . Studies with lapatinib in combination with other chemotherapies and partly with trastuzumab in primary breast cancer (PBC) are under way. Lapatinib is generally well tolerated; side effects can include diarrhoea, hand-foot-syndrome, nausea, vomiting, fatigue and rash. Long-term cardiotoxicity is not known but cardiac events are rare in trials conducted so far. Whether lapatinib is an effective alternative to trastuzumab has to be investigated in trials with a direct head-to-head comparison. Almost more interesting would be the answer to the question whether trastuzumab plus lapatinib can inhibit the HER2/EGFR pathway more than a monotherapy of each drug.
Vascular Epidermal Growth Factor Pathway
The concept of targeting the developing vascular supply of a new tumour (anti-angiogenic therapy) was introduced by Folkman in 1971 [8] . Angiogenesis is a process that describes the physiological as well as pathological generation of new blood vessels. While angiogenesis is a physiological process that occurs naturally and is controlled by 'on' and 'off' switches, building new blood vessels in malignant tumours seems to be an uncontrolled phenomenon. Malignant cells can alter endogenous angiogenic pathways and retard anti-angiogenic factors, thus providing an imbalance in blood vessel formation. Extensive laboratory data suggest that angiogenesis plays an essential role in breast cancer development, invasion, and metastasis [9] . Microscopic metastases are growth restricted (<2 mm) due to the need of oxygen and nutrients. They remain dormant until they undergo an 'angiogenic switch', presumably a result of further mutation. Hypoxia is a key signal for the induction of angiogenesis next to several other factors (interleukin-8, growth factors (EGF), oncogenes). Increased angiogenesis has been identified as an independent prognostic indicator for tumour recurrence and survival, with increased levels of angiogenesis and elevated tumour microvessel density linked with poor prognosis in multiple malignancies including breast cancer [10] . The vascular endothelial growth factor (VEGF) and its receptor (VEGFR) are key regulators of this process, promoting endothelial growth, migration, survival and blood vessel permeability [11] . Although an overexpression of VEGFR is associated with tumour progression and poor prognosis, in metastatic breast cancer VEGFR is not a predictive factor for an anti-angiogenic therapy. Anti-VEGF therapies reduce tumour vascularisation and therefore can inhibit tumour growth and metastasis. They can also reduce microvascular permeability and help to normalise irregular and leaky blood vessels and allow better delivery of chemotherapy to the tumour [12] . Published trials so far include metastatic breast cancer patients only. However, especially in locally advanced cancer disease one can think about the sense of anti-angiogenic treatments.
Bevacizumab (Avastin)
Bevacizumab was the second Food and Drug Administration (FDA)-approved humanised monoclonal antibody in metastatic breast cancer. It is directed against ligand A of the VEGFR. Like in anti-EGFR therapy, in combination with chemotherapy (paclitaxel) it was successful in first-line treatment of metastatic breast cancer [13] . However, in pretreated metastatic breast cancer, a combination of capecitabine and bevacizumab showed a lack of benefit in comparison to capecitabine alone, which may represent the poor prognosis due to tumour heterogeneity as well as the choice of chemotherapy [14] . In metastatic breast cancer patients, bevacizumab's combination partner seems to play a central role, as well as the line of therapy. Combinations with several agents like docetaxel [15, 16] , vinorelbin [17] , carboplatin, and nabpaclitaxel [18] were positively tested. However, in contrast to trastuzumab there is no predictive marker available that can define a subgroup of patients who benefit most from the treatment. Consequently, every patient with metastatic breast cancer can be treated in first line with bevacizumab. Bevacizumab has a very class-specific profile of side effects like hypertension and proteinuria. Its toxicity generally does not overlap with chemotherapy. In future trials, combination partners will change as well as the time point of treatment. It was suggested that angiogenesis occurs in the very early stages of tumour development (micrometastases), which gives a strong rationale for an adjuvant anti-angiogenic treatment. The Eastern Cooperative Oncology Group is planning an adjuvant feasibility trial evaluating bevacizumab in combination with dose-dense doxorubicin and cyclophosphamide followed by paclitaxel in women with node-positive primary breast cancer. TKIs of VEGFR are also known but are under clinical investigation (e.g. sorafenib and sunitinib). Their toxicity is characterised by fatigue, skin rashes, hand-foot-syndrome (HFS), and hypertension.
Combined Targeted Therapies
There are efforts to combine different kinds of targeted therapies to optimise progression-free as well as overall survival without chemotherapy toxicities.
Combination of Different Anti-HER2 Drugs
Whether an inhibition of the HER2 pathway by more than one agent is better than a monotherapy is an open question that will be answered by several phase II-III trials that are under way. Breast Cancer Symposium preliminary results of a one-arm phase II trial combining trastuzumab and pertuzumab in HER2-overexpressing metastatic breast cancer pretreated with trastuzumab and chemotherapies [19] . Pertuzumab is also a humanised antibody against HER2/neu, but is directed against a different part of the receptor. The clinical benefit rate was 39% and the progression-free survival was significantly better, without enhancing side effects (especially CCF). These results are promising due to the relatively high efficacy in a heavily pretreated cohort.
Whether the combination of lapatinib and trastuzmab is better than each of these agents alone is under investigation in several trials, e.g. ALTO.
Combination of Anti-VEGF and Anti-HER2 Pathways
A combination of bevacizumab and HER2 receptor blocking treatment appears very reasonable due to findings in preclinical and clinical studies that HER2 seems to play a central role in the regulation of VEGF [20, 21] . Several studies have demonstrated that blockade of the EGFR resulted in an antiangiogenic effect [22] . In a preclinical study, exposure to trastuzumab significantly decreased VEGF in HER2-overexpressing cells [23] . In vivo experiments have shown a reduction in xenograft volume using a combination of trastuzumab and bevacizumab compared with the single-agent control. Furthermore, in a cohort of 611 patients with primary breast cancer and a median follow-up of > 50 months, there was a significant positive association between HER2 and VEGF expression [24] . On the other hand, it was shown that VEGF is also able to regulate EGFR pathways. Data have suggested that an increased production of VEGF represents one mechanism by which tumour cells escape anti-EGFR monoclonal antibody therapy [25] . A phase I trial has evaluated the tolerability of the combination of bevacizumab with trastuzumab. It was determined that co-administration of these two humanised monoclonal antibodies did not alter the pharmacokinetics of either agent. The clinical responses were promising [26] . A phase III trial is under way (bevacizumab, trastuzumab and docetaxel as first-line therapy in HER2-positive metastatic breast cancer (AVEREL trial)).
One trial has tested the combination of bevacizumab and erlotinib, an EGFR TKI, in metastatic breast cancer. This combination demonstrated activity and also found that changes in circulating endothelial cells and circulating tumour cells may correlate with response to this combination [27] .
Combination of Anti-VEGF or Anti-HER2 Pathway with Other Pathway Inhibitors
Recently, new small molecules have been designed to block pathways deeper inside the tumour cell metabolism (e.g. phosphatase and tensin homologue deleted on chromosome 10 (PTEN), phosphatidylinositol 3-kinase (PI3K), mammalian target of rapamycin (mTOR) inhibitors). Theoretically, these new agents are also possible combination partners to chemotherapies as well as targeted therapies, but their value in cancer treatment has to be investigated in clinical trials.
Can Targeted Therapies Substitute for Chemotherapy?
So far, all trials investigating targeted therapies have shown a clear benefit from a combination of new molecules with chemotherapy. Monotherapies seem to have benefits as well, but they cannot reach the efficacy of combination therapies. Consequently, targeted therapies cannot substitute for chemotherapy today. However, in the near future, we will have to deal with major clinical problems: -What are the best 'targeted' combination partners in which setting? Will we still need anthracyclines for all patients in the adjuvant setting or only for some? How shall we deal with adjuvant pretreatment in the metastatic setting? -What is the best agent in which setting? TKIs or antibodies against HER2 or both? Anti-VEGF agents for all or only for subgroups? -What will we do when there is more than one targeted agent approved for the same clinical situation and when there is no head-to-head comparison available answering the important question which one is the optimal one? Chemotherapy will always play a major role in breast cancer treatment. However, its role is under investigation!
